Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.32 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.31 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15515404 | 0.71 | ACHE (0.33) | — | |
| SCHEMBL20590813 | 0.70 | CYP2C19 (0.38) | ALDH1A1LMNAPOLBCYP2C19CYP4F2 | |
| SCHEMBL320082 | 0.70 | CYP4F2 (0.35) | ALDH1A1LMNAPOLBCYP2C19CYP4F2 | |
| SCHEMBL16050402 | 0.70 | ACHE (0.32) | — | |
| SCHEMBL29131768 | 0.69 | ALDH1A1 (0.33) | ALDH1A1LMNAPOLBCYP2C19CYP4F2 | |
| SCHEMBL3942980 | 0.69 | CYP2C19 (0.32) | ALDH1A1LMNAPOLBCYP2C19 | |
| SCHEMBL19253462 | 0.68 | CYP4F2 (0.38) | ALDH1A1LMNAPOLBCYP2C19CYP4F2 | |
| SCHEMBL30203333 | 0.68 | ALDH1A1 (0.33) | ALDH1A1LMNAPOLBCYP2C19CYP4F2 | |
| SCHEMBL30483365 | 0.68 | CYP4F2 (0.36) | ALDH1A1LMNAPOLBCYP2C19CYP4F2 | |
| SCHEMBL26128925 | 0.67 | KDM5B (0.43) | ALDH1A1LMNAPOLBCYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111182898-B | Methods for treating huntington's disease | PTC医疗公司 | 2024-04-16 | — | — | CN | disclosed |
| EP-4347594-A1 | 2, 8-DIAZASPIRO [4.5] DECANE COMPOUNDS | Genentech, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| WO-2023193760-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI) , INC. (CN) | 2023-10-12 | — | — | WO | disclosed |
| EP-3644996-B1 | METHODS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2023-07-26 | — | — | EP | disclosed |
| WO-2023125627-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | LYNK PHARMACEUTICALS CO., LTD. (CN) | 2023-07-06 | — | — | WO | disclosed |
| WO-2022253341-A1 | 2, 8-DIAZASPIRO [4.5] DECANE COMPOUNDS | GENENTECH, INC. (US) | 2022-12-08 | — | — | WO | disclosed |
| CN-115003383-A | Bicyclic agonists of interferon gene stimulator STING | 斯克里普斯研究学院 | 2022-09-02 | — | — | CN | disclosed |
| US-11382918-B2 | Methods for treating Huntington's Disease | PTC THERAPEUTICS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20200163973-A1 | METHODS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. | 2020-05-28 | — | — | US | disclosed |
| CN-111182898-A | Methods for treating huntington's disease | PTC医疗公司 | 2020-05-19 | — | — | CN | disclosed |
| CN-111163838-A | Methods for treating huntington's disease | PTC医疗公司 | 2020-05-15 | — | — | CN | disclosed |
| US-20200147087-A1 | METHODS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. | 2020-05-14 | — | — | US | disclosed |
| EP-3644996-A1 | METHODS FOR TREATING HUNTINGTON'S DISEASE | PTC Therapeutics, Inc. (US) | 2020-05-06 | — | — | EP | disclosed |
| EP-3645121-A1 | METHODS FOR TREATING HUNTINGTON'S DISEASE | PTC Therapeutics, Inc. (US) | 2020-05-06 | — | — | EP | disclosed |
| WO-2019005980-A1 | METHODS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. (US) | 2019-01-03 | — | — | WO | disclosed |
| WO-2019005993-A1 | METHODS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. (US) | 2019-01-03 | — | — | WO | disclosed |
| WO-2019000237-A1 | 3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME CORP. (US) | 2019-01-03 | — | — | WO | disclosed |
| US-20110257014-A1 | 1-(Heteroaryl)pyrazol-4-ylacetic acids, processes for their preparation and their use as herbicides and plant growth regulators | BAYER CROPSCIENCE AG (DE) | 2011-10-20 | — | — | US | disclosed |
| WO-2011073098-A1 | 1-(HETEROARYL)-PYRAZOL-4-YL-ACETIC ACIDS, METHOD FOR THE PRODUCTION THEREOF, AND THE USE THEREOF AS HERBICIDES AND PLANT GROWTH REGULATORS | BAYER CROPSCIENCE AG (DE) | 2011-06-23 | — | — | WO | disclosed |
| US-20090118305-A1 | PYRIDINE AND PYRAZINE DERIVATIVES - 083 | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200163973-A1 | METHODS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, PARK7 | ALDH1A1 2514/4885LMNA 1633/4885POLB 831/4885 |
| US-20200147087-A1 | METHODS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, RECQL | ALDH1A1 1120/4885LMNA 1855/4885POLB 819/4885 |
| US-20110257014-A1 | 1-(Heteroaryl)pyrazol-4-ylacetic acids, processes for their preparation and their use as herbicides and plant growth regulators | DDT, HPD, DDC | ALDH1A1 378/4885LMNA 4090/4885POLB 3238/4885 |
| US-20090118305-A1 | PYRIDINE AND PYRAZINE DERIVATIVES - 083 | MKI67, CCND3, CCND1 | ALDH1A1 802/4885LMNA 2005/4885POLB 2167/4885 |
| US-11382918-B2 | Methods for treating Huntington's Disease | HTT, HYPK, PARK7 | ALDH1A1 2514/4885LMNA 1633/4885POLB 831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.